Regeneron Pharmaceuticals Q1 one-off charges to be ~$56M
Regeneron Pharmaceuticals (NASDAQ:REGN) said on MondayÂ that its Q1 acquired in-process research and development charges will be ~$56M on a pretax basis.
The charge is related to an up-front payment for collaboration and license agreement with Sonoma Biotherapeutics.
The one-off charge will impact GAAP and non-GAAP EPS by ~$0.42.